StreetAlpha.app
Home › Stocks › EDIT

Editas Medicine, Inc. (EDIT)

Healthcare
$1.82
▼ −2.41%
LAST CLOSE · NOV 17

Editas Medicine develops CRISPR-based gene editing medicines for serious diseases from Cambridge, Massachusetts. It last closed at $1.82 on Nov 17, down 2.41% on the day. The average 12-month price target from 2 analysts is $5.50 (+201.4% from the last close), with a high of $6.00 and a low of $5.00. In the past 30 days there were 1 dark pool print totaling $790K, the largest $790K.

AI Auto Pilots
Is EDIT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$49.8M
+7.4% vs a year ago
Net income
−$72.2M
−145.0% margin
EPS (diluted)
−$0.54
Free cash flow
−$110.5M
−221.7% margin
Valuation
Market cap
$281.7M
154.3M shares
P/E
–
No P/E while losing money
Price to sales
5.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$93.2M
At Sep 30
Debt
$56.8M
At Sep 30
Shareholder equity
$84.5M
Shares outstanding
154.3M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $25.5M$25.5MFY2021FY2022: $19.7M$19.7MFY2022FY2023: $78.1M$78.1MFY2023FY2024: $32.3M$32.3MFY2024FY2025: $40.5M$40.5MFY2025

From EDIT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated EDIT in the past 90 days, not enough for a consensus
Average 12-month target
$5.50
▲ 201.4% upside

Based on 2 analysts who set a price target on EDIT in the past 90 days. The average target is $5.50, with a high of $6.00 and a low of $5.00, compared with the last close of $1.82.

Low $5.00Avg $5.50High $6.00
Blue marker: last close $1.82
Highest target$6.00
Average target$5.50
Lowest target$5.00
Latest rating changes
Wells FargoUpgrade
Oct 8Buy$6
GuggenheimUpgrade
Sep 23Buy$5
Ladenburg ThalmannInitiated
Aug 18Buy$6
DateFirmActionRatingPrice target
Oct 8Wells FargoUpgradeBuy$6
Sep 23GuggenheimUpgradeBuy$5
Aug 18Ladenburg ThalmannInitiatedBuy$6
Loading…

Technical Analysis

EDIT · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 36% below its 20 day and 41% below its 50 day average. It is 48% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot S1 at $1.78, and the nearest resistance the Pivot at $1.86.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 12.3%/day
Key levels
$3.9452 week high+116.5%
$2.80100 day average+53.8%
$2.70200 day average+48.4%
$2.67Swing high (Oct 20)+46.7%
$2.5850 day average+41.8%
$2.4820 day average+36.3%
$1.90Pivot R1+4.4%
$1.86Pivot+2.2%
$1.82Last close
$1.78Pivot S1−2.2%
$1.6652 week low−8.8%
Indicators
RSI (14)31.90Weak, oversold below 30Neutral
MACD-0.16Below its signal lineBearish
Stochastic5.8Near the bottom of its rangeOversold
ADX (14)14.1No clear trend
Williams %R-99.6Oversold below −80, overbought above −20Oversold
CCI (20)-200.9Oversold below −100, overbought above 100Oversold
Rate of change−29.8%Change over 10 sessionsBearish
ATR (14)$0.22Typical daily range, 12.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for EDIT

What happened before

See how EDIT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow EDIT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How EDIT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in EDIT in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$790K
Largest print
$790K
Loading…

EDIT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲105 buying vs 88 selling
  • ▲Held by funds +12.4 pts
  • ●Funds holding +1
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding219218+0.5%
In funds' top 10110.0%
Held by funds90.3%78.0%+12.4 pts
New / increased32 / 7335 / 77−6.3%
Reduced / sold out58 / 3040 / 24+37.5%
Put/call ratio0.020.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EDIT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EDIT is in one of them and how their past EDIT trades turned out.

EDIT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EDIT in an article yet. Here's the latest on the wider market.

EDIT Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed May 19
Who traded EDIT · since 2017
Latest 5 filings of 14
$1K – $15KTraded Apr 10, 2023Filed May 19, 2023
$1K – $15KTraded Apr 14, 2021Filed May 1, 2021
$1K – $15KTraded Mar 2, 2021Filed Apr 1, 2021
$1K – $15KTraded Nov 17, 2020Filed Dec 1, 2020
$1K – $15KTraded May 1, 2020Filed May 31, 2020
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KApr 10, 2023May 19, 202339 d
Don BeyerD · VASell$1K – $15KApr 14, 2021May 1, 202117 d
Don BeyerD · VASell$1K – $15KMar 2, 2021Apr 1, 202130 d
Don BeyerD · VABuy$1K – $15KNov 17, 2020Dec 1, 202014 d
Don BeyerD · VASell$1K – $15KMay 1, 2020May 31, 202030 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Editas Medicine

Editas Medicine is a gene editing company based in Cambridge, Massachusetts. It develops medicines that use CRISPR technology to edit DNA inside the body, aiming to treat serious diseases, and its lead experimental candidate targets high cholesterol. The company also licenses its gene editing technology to partners such as Bristol Myers Squibb and Vertex Pharmaceuticals, which use it for medicines in other therapeutic areas.

Headquarters
Cambridge, MA
Founded
2013